Concepedia

Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma

Bodoor Yaseen, Henry Lopez, Zeinab Taki, Sara Zafar, Henrique Rosario, Bahja Ahmed Abdi, Shivanee Vigneswaran, Fiona Xing, Nikita Arumalla, Simon Black,

Lara D. Veeken · 2020 · 47 citations · 27 references

DOI

Abstract

IL-31/IL-31RA is confirmed as a candidate pro-fibrotic pathway, which may contribute to skin and lung fibrosis in a subset of scleroderma patients.

References

27

Near-optimal probabilistic RNA-seq quantification

Nicolas Bray, Harold Pimentel, Páll Melsted et al. · Nature Biotechnology · 2016 · 10.4K citations

, , +7

2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen et al. · Arthritis & Rheumatism · 2013 · 3.3K citations · Full text

Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Oliver Distler, Kristin B. Highland, Martina Gahlemann et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Donald P. Tashkin, Michael D. Roth, Philip J. Clements et al. · The Lancet Respiratory Medicine · 2016 · 1K citations · Full text

, , +9

Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

Stacey R. Dillon, Cindy A. Sprecher, Angela Hammond et al. · Nature Immunology · 2004 · 982 citations

, , +11